Based in the Netherlands and the US, uniQure has appointed Matthew Kapusta as its chief executive officer.
Kapusta had previously served as the gene therapy specialist’s interim chief executive since September last year, as well as chief financial officer since January 2015.
Prior to this, Kapusta was senior vice president of medical devices firm AngioDynamics between 2011 and 2014, and has also served as vice president of finance for Smith & Nephew Orthopeadics.
He brings over 10 years of investment banking experience specialising in life sciences, which includes serving as managing director of healthcare investment banking at Collins Stewart.
Kapusta said: “I am honoured and grateful for the trust that the board has placed in me to lead uniQure at this important stage in the company’s evolution.
“This is an exciting time for uniQure, and I am fully committed to the company’s success and the execution of our core strategic goals.
“As we head into 2017, we are fully focused on achieving several important catalysts, including rapidly progressing our hemophilia B programme into late-stage development and advancing our gene therapy candidates for congestive heart failure and Huntington’s disease into the clinic.”